UK-based Virax Biolabs Group Limited has started distribution of Monkeypox Virus Antigen Rapid Test Kits, which were launched in markets accepting CE mark like the European Union.

The test kits are for use in point of care settings and to assist healthcare professionals to identify a monkeypox infection in persons suspected of carrying the monkeypox virus. Results are obtained usually in 15 minutes, said Virax Biolabs Group.

According to the company, its Monkeypox Virus Antigen Rapid Test Kits also provide an important initial screening test for persons who have been exposed to monkeypox-infected patients or in a high-risk environment.

James Foster — Virax Biolabs Group CEO said: “I am very proud of our organization’s ability to quickly bring this rapid antigen test kit to market to help combat the monkeypox outbreak. We are working diligently to distribute the kits as well as the previously announced Monkeypox and Varicella Zoster Viruses Real Time PCR Detection Kits into the hands of healthcare practitioners as quickly as possible.”

The Monkeypox Virus Antigen Rapid Test Kits are employed for in vitro qualitative detection of the monkeypox virus antigen in the throat swabs and skin exudates of humans by colloidal gold immunochromatography.

  EU, European Union, Monkeypox, Monkeypox Virus Antigen Rapid Test Kits, Virax Biolabs, Virax Biolabs Group Limited